Olanib 150 mg contains the active pharmaceutical ingredient Olaparib, a very potent oral PARP (poly ADP-ribose polymerase) inhibitor used primarily in cancer treatment for certain types of cancer. Manufactured under strict pharmaceutical guidelines, Olanib is a class of medicines known as targeted cancer therapies. It works by interfering with the DNA repair system in cancer cells, thereby preventing their growth and proliferation.

Mechanism of Action

Olaparib particularly targets the PARP enzyme, which is crucial in repairing DNA damage within cells. BRCA1 or BRCA2 gene-deficient cancer cells rely heavily on PARP to survive. With Olanib inhibiting PARP, it triggers the build-up of DNA damage within such cells, leading to cell death without disrupting most normal cells. This targeted action makes Olanib a viable alternative for BRCA-mutated cancer patients.

Indications

Olanib 150 mg can be used in the treatment of various types of cancer, particularly among patients having inherited or acquired BRCA gene mutations. It is prescribed for:

Ovarian Cancer: Adult patients with platinum-sensitive relapsed ovarian cancer, maintaining response (partial or complete) to platinum-based therapy.

Breast Cancer: Germline BRCA-mutated, HER2-negative metastatic breast cancer patients who have previously received chemotherapy.

Pancreatic Cancer: Used in maintenance therapy in adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.

Prostate Cancer: Used in metastatic castration-resistant prostate cancer with HRR gene mutations, including BRCA1/2.

Dosage and Administration

The dose of Olanib taken should be 150 mg orally twice daily (300 mg total daily) with or without food. The tablets should be swallowed whole and never chewed or crushed. Dosage may be adjusted based on individual patient tolerability, side effects, or drug interactions.

Patients need to follow oncologist prescription very closely. Never change or stop medication without consulting a healthcare provider.

Precautions and Warnings

The patient, before undergoing treatment with Olanib, should inform the doctor of any history of:

Low blood cell count or blood disorders

Liver or kidney problems

Lung or respiratory disease history
Respiratory illness

Other prescription, over-the-counter, or herbal medications

Olanib should not be used during pregnancy except in unavoidable circumstances. Contraception should be practiced during treatment and for a period afterward, as Olaparib can harm an unborn baby. Breastfeeding should not be performed during treatment and for a period following the last dose.

Side Effects

Certain typical side effects of Olanib 150 mg may be:

Nausea and vomiting

Weakness or fatigue

Low red blood cells (anemia)

Diarrhea or constipation

Decreased appetite

Headache

Shortness of breath

Severe but infrequent side effects include myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) and pneumonitis. Blood tests and clinical signs have to be monitored closely throughout the course of treatment.

Drug Interactions

Olanib is expected to interact with certain drugs, including potent or moderate CYP3A inhibitors and inducers. They include antifungal drugs like ketoconazole, antibiotics like clarithromycin, and anticonvulsants like phenytoin. In such combinations of drugs, dose adjustment or close monitoring could be required.

Storage Instructions

Store Olanib tablets at room temperature (68°F to 77°F, 20°C to 25°C) in the original package. Keep it away from heat, moisture, and direct sunlight. Store it out of the reach of children and pets.